Fig. 3

HSDL2 downregulation promotes the proliferation, migration, and invasion of cholangiocarcinoma (CCA) cells by inhibiting the P53 pathway. A Scatter plot of differentially expressed genes determined using transcriptome sequencing. B KEGG classification and enrichment analysis was performed with differentially expressed genes. C KEGG enrichment analysis was performed on differentially expressed genes enriched in the “cell growth and death” gene set. D, E RBE-sh#Ctrl, RBE-shHSDL2#1, RBE-shHSDL2#3, HCCC9810-Vector, and HCCC9810-HSDL2 cells were subjected to qRT-PCR (D) and western blotting with indicated antibodies (E). F The expression of P53 was analyzed using immunofluorescence staining. G-J RBE-sh#Ctrl and RBE-shHSDL2#3 cells transfected with vector or P53 plasmids (G, I), as well as HCCC9810-Vector and HCCC9810-HSDL2 cells transfected with si#ctrl or siP53 (H, J), were subjected to cell proliferation assay. K Image of xenograft tumors. L–M RBE-sh#Ctrl and RBE-shHSDL2#3 cells transfected with vector or P53 plasmids (L), as well as HCCC9810-Vector and HCCC9810-HSDL2 cells transfected with si#ctrl or siP53 siRNAs (M), were subjected to invasion and migration assays. Data are presented as mean ± SD (n=3). *p < 0.05, **p < 0.01, and ***p < 0.001